MedTrace Logo

Early Antibiotic Discontinuation in FUO

NCT02906254 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 123

Last updated 2016-09-20

No results posted yet for this study

Summary

Febrile neutropenia requires prompt initiation of broad-spectrum antibiotics, which can be responsible for side-effects and selection of resistance. This study demonstrates the safety of an early discontinuation of empirical treatments, in carefully selected patients presenting with fever of unknown origin.

Conditions

Interventions

OTHER

ECIL-4 guidelines group

Antibiotics were stopped when patients had been afebrile for more than 48 hours

OTHER

Short-course antibiotic therapy

Antibiotics were stopped on day 5 in febrile or afebrile patients

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Principal Investigators

  • Gaelle Guillerm, MD · Department of Hematology, Brest Teaching Hospital, Hospital Morvan, Avenue Foch, 29200 Brest, France

  • Jean-Philippe Talarmin, MD · Department of Internal Medicine, Infectious Diseases and Hematology, Cornouaille Hospital Quimper, Avenue Yves Thépot, 29000 Quimper, France

  • Lenaïg Le Clech, MD · Department of Hematology, Brest Teaching Hospital, Hospital Morvan, Avenue Foch, 29200 Brest, France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02906254 on ClinicalTrials.gov